dc.contributor.author | Ünal, Çağlar | |
dc.contributor.author | Azizy, Abdulmunir | |
dc.contributor.author | Karabulut, Senem | |
dc.contributor.author | Taştekin, Didem | |
dc.contributor.author | Akyıldız, Arif | |
dc.contributor.author | Yaşar, Serkan | |
dc.contributor.author | Yalçın, Şuayib | |
dc.contributor.author | Çoban, Eyüp | |
dc.contributor.author | Evrensel, Türkkan | |
dc.contributor.author | Kalkan, Ziya | |
dc.contributor.author | Sağlam, Sezer | |
dc.date.accessioned | 2023-10-27T09:42:33Z | |
dc.date.available | 2023-10-27T09:42:33Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S. ... Sağlam, S. (2023). Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish oncology group. The Oncologist, 28(10), 875-884. https://dx.doi.org/10.1093/oncolo/oyad257 | en_US |
dc.identifier.issn | 1083-7159 | |
dc.identifier.issn | 1549-490X | |
dc.identifier.uri | https://dx.doi.org/10.1093/oncolo/oyad257 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/11656 | |
dc.description.abstract | Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).Methods: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.Results: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second-and =third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.Conclusions and Relevance: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Oxford University Press | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Capecitabine | en_US |
dc.subject | CAPTEM | en_US |
dc.subject | Neuroendocrine Neoplasia | en_US |
dc.subject | Neuroendocrine Tumors | en_US |
dc.subject | Temozolomide | en_US |
dc.title | Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish oncology group | en_US |
dc.type | article | en_US |
dc.relation.ispartof | The Oncologist | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-2538-8569 | en_US |
dc.identifier.volume | 28 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.startpage | 875 | en_US |
dc.identifier.endpage | 884 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1093/oncolo/oyad257 | en_US |
dc.institutionauthor | Sakin, Abdullah | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001063354900001 | en_US |
dc.identifier.scopus | 2-s2.0-85174080160 | en_US |
dc.identifier.pmid | 37676712 | en_US |
dc.identifier.scopusquality | Q1 | en_US |